Alumis (NASDAQ:ALMS) Now Covered by Oppenheimer

Oppenheimer started coverage on shares of Alumis (NASDAQ:ALMS) in a research note released on Thursday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $32.00 target price on the stock.

Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Baird R W upgraded Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $26.00 price objective on shares of Alumis in a research note on Monday, January 6th. Finally, Robert W. Baird started coverage on Alumis in a research report on Thursday, October 31st. They set an “outperform” rating and a $25.00 target price for the company. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $27.57.

Alumis Trading Up 2.9 %

Shares of NASDAQ ALMS opened at $6.72 on Thursday. The business’s 50 day moving average is $8.16 and its 200-day moving average is $10.47. Alumis has a 1-year low of $6.29 and a 1-year high of $13.53.

Institutional Investors Weigh In On Alumis

A number of institutional investors and hedge funds have recently made changes to their positions in ALMS. Samsara BioCapital LLC purchased a new stake in shares of Alumis during the third quarter valued at approximately $34,886,000. Towerview LLC increased its position in shares of Alumis by 22.6% during the 3rd quarter. Towerview LLC now owns 380,000 shares of the company’s stock valued at $4,058,000 after purchasing an additional 70,000 shares during the last quarter. Geode Capital Management LLC bought a new stake in shares of Alumis during the 3rd quarter worth $3,266,000. Millennium Management LLC purchased a new position in shares of Alumis in the 2nd quarter worth about $3,376,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Alumis in the third quarter valued at about $1,160,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.